DIPRIVAN Drug Patent Profile

Which patents cover Diprivan, and what generic alternatives are available?

Diprivan is a drug marketed by Fresenius Kabi Usa and is included in one NDA. There is one patent protecting this drug.

This drug has one patent family member in one country.

The generic ingredient in DIPRIVAN is propofol. There are twelve drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the propofol profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Diprivan

A generic version of DIPRIVAN was approved as propofol by SAGENT PHARMS INC on January 4^th, 1999.

Summary for DIPRIVAN

International Patents:	1
US Patents:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	135
Clinical Trials:	142
Patent Applications:	3,907
Drug Prices:	Drug price information for DIPRIVAN
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for DIPRIVAN
What excipients (inactive ingredients) are in DIPRIVAN?	DIPRIVAN excipients list
DailyMed Link:	DIPRIVAN at DailyMed

See drug prices for DIPRIVAN

Recent Clinical Trials for DIPRIVAN

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University of Alabama at Birmingham	Phase 1
Hartford Hospital	Phase 4
Zhejiang Cancer Hospital	N/A

See all DIPRIVAN clinical trials

Pharmacology for DIPRIVAN

Drug Class	General Anesthetic
Physiological Effect	General Anesthesia

US Patents and Regulatory Information for DIPRIVAN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Fresenius Kabi Usa	DIPRIVAN	propofol	INJECTABLE;INJECTION	019627-001	Oct 2, 1989		DISCN	No	No
Fresenius Kabi Usa	DIPRIVAN	propofol	INJECTABLE;INJECTION	019627-002	Jun 11, 1996	AB	RX	Yes	Yes

Expired US Patents for DIPRIVAN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Fresenius Kabi Usa	DIPRIVAN	propofol	INJECTABLE;INJECTION	019627-002	Jun 11, 1996
Fresenius Kabi Usa	DIPRIVAN	propofol	INJECTABLE;INJECTION	019627-002	Jun 11, 1996
Fresenius Kabi Usa	DIPRIVAN	propofol	INJECTABLE;INJECTION	019627-002	Jun 11, 1996
Fresenius Kabi Usa	DIPRIVAN	propofol	INJECTABLE;INJECTION	019627-002	Jun 11, 1996

International Patents for DIPRIVAN

See the table below for patents covering DIPRIVAN around the world.

Country	Patent Number	Title	Estimated Expiration
European Patent Office	0814787	EMULSIONS HUILE DANS L'EAU CONTENANT DU PROPOFOL ET DE L'EDETATE DISODIQUE (OIL IN WATER EMULSIONS CONTAINING PROPOFOL AND DISODIUM EDETATE)
Germany	69534696
Germany	19509828
Slovakia	287511
United Kingdom	2298789	Pharmaceutical compositions
World Intellectual Property Organization (WIPO)	9629064

Market Dynamics and Financial Trajectory for DIPRIVAN (Propofol)

Introduction

DIPRIVAN, the brand name for the drug propofol, is a widely used intravenous general anesthetic and sedation drug. Its impact on the medical field, particularly in anesthesia and ICU sedation, has been significant. Here, we delve into the market dynamics and financial trajectory of DIPRIVAN, highlighting key trends, drivers, and projections.

Global Market Size and Growth

The global propofol market, which includes DIPRIVAN, is estimated to be substantial and growing. As of 2024, the global propofol market size was valued at USD 1352.2 million[1].

Compound Annual Growth Rate (CAGR)

The market is expected to expand at a compound annual growth rate (CAGR) of 10.80% from 2024 to 2031. This growth is driven by various factors, including the increasing demand for surgical procedures and advancements in healthcare infrastructure[1].

Regional Market Analysis

North America

North America holds a significant share of the global propofol market, accounting for approximately 40% of the global revenue, with a market size of USD 540.88 million in 2024. The region is expected to grow at a CAGR of 9.0% from 2024 to 2031, driven by the growing prevalence of chronic diseases and advancements in healthcare technology[1].

Europe

Europe accounts for around 30% of the global revenue, with a market size of USD 405.66 million in 2024. The European market is projected to grow at a CAGR of 9.3% from 2024 to 2031, driven by investments in expanding surgical capacities and stringent regulatory standards ensuring product quality and safety[1].

Asia-Pacific

The Asia-Pacific region is the fastest-growing market, with a market size of USD 311.01 million in 2024 and a projected CAGR of 12.8% from 2024 to 2031. This rapid growth is attributed to expanding healthcare infrastructure, an aging population, and rising healthcare expenditure in countries like China and India[1].

Middle East and Africa

The Middle East and Africa region holds a smaller but growing share, with a market size of USD 27.04 million in 2024 and a projected CAGR of 10.5% from 2024 to 2031. The growth here is driven by expanding healthcare infrastructure and increasing investments in medical services[1].

Key Drivers of Market Growth

Increasing Demand for Surgical Procedures

The rising need for surgical interventions, particularly in regions with aging populations and increasing prevalence of chronic diseases, is a significant driver of the propofol market. This includes both inpatient and outpatient procedures, with ambulatory surgery centers gaining popularity[1][2].

Advancements in Healthcare Infrastructure and Technology

Improvements in healthcare infrastructure and technological advancements in anesthesia delivery systems enhance the efficiency and safety of propofol administration. This includes the adoption of total intravenous anesthesia (TIVA) and the use of laryngeal mask airways[2].

Government Initiatives and Reimbursement Policies

Favourable government initiatives and reimbursement policies contribute to the market growth by making propofol more accessible and affordable for patients undergoing surgical procedures[1].

Market Segments

General Anesthesia

General anesthesia remains the dominant segment, given its essential role in various surgical procedures. This segment is expected to continue growing as surgical volumes increase globally[1].

Procedural Sedation

Procedural sedation is another significant segment, particularly in regions like Europe, where it is the fastest-growing segment. This is driven by the increasing demand for minimally invasive treatments and outpatient procedures[1].

Competitive Landscape

Key Manufacturers

Fresenius Kabi, the manufacturer and distributor of DIPRIVAN, is a major player in the US market and supplies propofol to over 150 countries. Other key manufacturers include Bachem, Curia, SI Group, and several others[2][4].

Market Share

In 2022, the top five players in the global propofol market held approximately 75.46% of the market share in terms of revenue[4].

Financial Trajectory

Revenue Projections

The global propofol market is expected to continue its upward trajectory, with significant revenue growth projected from 2024 to 2031. The market size is anticipated to expand from USD 1352.2 million in 2024 to a substantially higher figure by 2031, driven by the factors mentioned above[1][3].

Historical Performance

Historically, Fresenius Kabi has demonstrated its ability to meet market demands, particularly during the 2009-2013 propofol shortage. The company ramped up production using its multiple worldwide manufacturing facilities, ensuring a reliable supply of DIPRIVAN[2].

Challenges and Opportunities

Supply Chain Management

Managing supply chains effectively is crucial, especially given past shortages. Manufacturers like Fresenius Kabi have shown resilience in meeting demand during such periods[2].

Regulatory Compliance

Compliance with stringent regulatory standards is essential for maintaining market confidence. Manufacturers must ensure that their products meet these standards to foster consumer trust and market growth[1].

Emerging Markets

Emerging markets, particularly in the Asia-Pacific region, offer significant opportunities for growth due to their expanding healthcare infrastructure and increasing healthcare expenditure[1].

Conclusion

The market dynamics for DIPRIVAN (propofol) are characterized by strong growth driven by increasing demand for surgical procedures, advancements in healthcare infrastructure, and favourable government initiatives. The financial trajectory indicates a promising future with significant revenue growth projected over the next several years.

Key Takeaways

• The global propofol market is expected to grow at a CAGR of 10.80% from 2024 to 2031.
• North America, Europe, and Asia-Pacific are key regions driving market growth.
• General anesthesia and procedural sedation are significant market segments.
• Fresenius Kabi is a major player in the propofol market.
• Emerging markets and advancements in healthcare technology offer significant growth opportunities.

FAQs

What is the current market size of the global propofol market?

The global propofol market size was estimated at USD 1352.2 million in 2024[1].

What is the projected CAGR for the global propofol market from 2024 to 2031?

The global propofol market is expected to grow at a CAGR of 10.80% from 2024 to 2031[1].

Which region is the fastest-growing market for propofol?

The Asia-Pacific region is the fastest-growing market for propofol, with a projected CAGR of 12.8% from 2024 to 2031[1].

What are the key drivers of the propofol market growth?

Key drivers include increasing demand for surgical procedures, advancements in healthcare infrastructure and technology, and favourable government initiatives and reimbursement policies[1][2].

Who are the major manufacturers of propofol?

Major manufacturers include Fresenius Kabi, Bachem, Curia, SI Group, and several others[2][4].

Sources

1. Cognitive Market Research: Propofol market Will Grow at a CAGR of 10.80% from 2024 to 2031.
2. Diprivan: How Propofol Transformed the Practice of Anesthesia.
3. Market Research Intellect: Global Propofol Injection Market Size, Trends and Projections.
4. Market Research: Global Propofol Market Insights, Forecast to 2029.
5. Drugs.com: Diprivan: Package Insert / Prescribing Information.